Law360, Chicago (March 26, 2018, 4:13 PM EDT) -- An Illinois federal jury on Monday found AbbVie Inc.'s AndroGel product caused an Oregon man's heart attack and ordered the company to pay him more than $3 million, a verdict that came in the latest bellwether trial in the multidistrict litigation over testosterone replacement therapy drugs.
The verdict came at the end of a more than two-week trial and was the second time a jury has considered whether the man's heart attack was caused by his AndroGel use. Shown is an unrelated 2007 arbitration hearing. (AP) The jury awarded plaintiff Jesse Mitchell $200,000 in compensatory damages and $3 million in punitive damages...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!